Swedish study questions safety of GE's Visipaque CT agent
This article was originally published in Clinica
Executive Summary
Contrary to previous findings, patients undergoing CT-guided percutaneous coronary interventions (PCI) using GE Healthcare's contrast agent Visipaque (iodixanol) are twice as likely to experience renal failure than those receiving alternative agents, Hexabrix (ioxaglate) or Omnipaque (iohexol). So say results of a study of over 50,000 patients presented at last month's annual meeting of the Radiological Society of North America (RSNA), in Chicago.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.